免疫疗法
免疫系统
PD-L1
医学
体细胞
CD8型
计算生物学
生物标志物
生物信息学
免疫检查点
免疫学
生物
基因
遗传学
作者
Jean David Fumet,Caroline Truntzer,Mark Yarchoan,François Ghiringhelli
标识
DOI:10.1016/j.ejca.2020.02.038
摘要
Treatment with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer types, but only in a subset of patients. The use of predictive biomarkers for response to PD-1/PD-L1 inhibitors is critical for patient selection. Expression of PD-L1 has demonstrated utility in patient selection. Tumour mutational burden (TMB) is an emerging biomarker for response to PD-1/PD-L1 inhibitors. The evaluation of this biomarker is based on the hypothesis that a high number of mutations in somatic exonic regions will lead to an increase in neoantigen production, which could then be recognised by CD8+ T cells, resulting in improved immune responses. In this review, we will discuss rationale and implementation of TMB usage in patients, development of different methods to assess it, current limitations and technical issues to use this biomarker as a diagnostic test and propose future perspectives beyond TMB.
科研通智能强力驱动
Strongly Powered by AbleSci AI